D-2-Hydroxyglutarate in Glioma Biology

Fu-Ju Chou; Yang Liu; Fengchao Lang; Chunzhang Yang

doi:10.3390/cells10092345

Cells (Sep 2021)

D-2-Hydroxyglutarate in Glioma Biology

Fu-Ju Chou,
Yang Liu,
Fengchao Lang,
Chunzhang Yang

Affiliations

Fu-Ju Chou: Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA
Yang Liu: Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA
Fengchao Lang: Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA
Chunzhang Yang: Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA

DOI: https://doi.org/10.3390/cells10092345
Journal volume & issue: Vol. 10, no. 9
p. 2345

Abstract

Read online

Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an “oncometabolite”, D-2-hydroxyglutarate (D-2-HG). Abnormally elevated D-2-HG levels result in a distinctive pattern in cancer biology, through competitively inhibiting α-ketoglutarate (α-KG)/Fe(II)-dependent dioxgenases (α-KGDDs). Recent studies have revealed that D-2-HG affects DNA/histone methylation, hypoxia signaling, DNA repair, and redox homeostasis, which impacts the oncogenesis of IDH-mutated cancers. In this review, we will discuss the current understanding of D-2-HG in cancer biology, as well as the emerging opportunities in therapeutics in IDH-mutated glioma.

Published in Cells

ISSN: 2073-4409 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General): Cytology
Website: https://www.mdpi.com/journal/cells

About the journal

Abstract

Keywords